<DOC>
	<DOCNO>NCT02167321</DOCNO>
	<brief_summary>The introduction total mesorectal excision ( TME ) progress neoadjuvant chemoradiotherapy significantly reduce risk local recurrence locally advanced rectal cancer . However , systemic recurrence rate improve consider cause unsatisfactory overall survival patient rectal cancer . Relatively high systemic relapse rate local recurrence rate probably due insufficient control systemic micrometastasis adjuvant chemotherapy . The efficacy adjuvant combination cytotoxic chemotherapy surgery treatment rectal cancer remain controversial . In addition , preoperative radiotherapy increase surgical complication anastomosis site leakage radiotherapy worsen sexual urinary function bowel habit result aggravation quality life . Furthermore preoperative chemoradiotherapy upto 3 month extend treatment period increase cost care . To reduce possibility overtreatment , need confirm preoperative chemoradiotherapy absolutely necessary locally advanced rectal cancer patient safe circumferential margin ( CRM ) resect curatively standardized TME operation . In study , investigator aim evaluate efficacy adjuvant FOLFOX chemotherapy TME without preoperative chemoradiotherapy patient locally advanced rectal cancer spar CRM inferior current standard treatment .</brief_summary>
	<brief_title>Rectal Cancer , Adjuvant Chemotherapy , FOLFOX ( 5-fluorouracil/Leucovorin/Oxaliplatin ) , Total Mesorectal Excision</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma rectum 10 cm anal verge 2 . Locally advanced rectal cancer ( T3N0 T13N+ ) 3 . Age : 1980 year old . 4 . Without evidence distant metastasis include paraortic lymph node , common &amp; external iliac lymph node metastasis 5 . MRI scan confirm 2 mm circumferential margin 6 . ECOG ( Eastern Cooperative Oncology Group ) performance status 02 7. preoperative ASA class IIII 8 . No prior systemic treatment rectal cancer ( i.e . chemotherapy immunotherapy ) 9 . No history regional radiation treatment pelvic cavity 10 . Adequate hematologic function : ANC ( absolute neutrophil count ) ≥ 1.5×109/L，Platelet ≥ 100×109/L , Adequate renal function : Cr ≤ 1.5×ULN Glomerular filtration rate ( Ccr calculate Cockcroft formula ) ≥ 50 ml/min , Adequate hepatic function : ALT ( Alanine aminotransferase ) /AST ( aspartate aminotransferase ) ≤ 2.5×ULN , Total bilirubin ≤ 1.5×ULN 11 . Patients must willing able comply protocol duration study 12 . Signed informed consent 1 . Malignancy rectum adenocarcinoma adenocarcinoma develop inflammatory bowel disease 2 . Suspicious distant metastasis 3 . Patients peripheral neuropathy ≥ NCI CTC ( common terminology criterion ) grade 1 4 . Uncontrolled significant cardiovascular disease ( i.e . NYHA ( New York Heart Association ) class III IV heart failure , myocardial infarction within past 6 month , uncontrolled angina pectoris ) 5 . Uncontrolled active infection serious concomitant systemic disorder incompatible study 6 . Other coexist malignancy malignancy within past 5 year , exception adequately treat situ carcinoma cervix basal cell carcinoma skin 7 . Patients require immunosuppressive treatment receive organ transplantation 8 . Uncontrolled epilepsy psychiatric disease 9 . Pregnant lactate patient 10 . Females positive pregnancy test unless childbearing potential otherwise exclude ( amenorrheic least 2 year , hysterectomy oophorectomy ) 11 . Patients receive concomitant treatment drug interact 5Fluorouracil oxaliplatin flucytosine , phenytoin , warfarin 12 . Prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity 5Fluorouracil know dihydropyrimidine dehydrogenase ( DPD ) deficiency . 13 . Known hypersensitivity platinumbased drug , leucovorin capecitabine 14 . Patients take sorivudine brivudine 15 . Patients take tegafur , gimeracil , oteracil potassium complex stop medication within 7days . 16 . Patients hereditary disease like galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption , etc . 17 . Participant clinical trial within 4 week initiation study 18 . Treatment bevacizumab , cetuximab , oxaliplatin irinotecan screening</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>